Scarica l'app Stockscreener
26.63
5.22%
1.32
Dopo l'orario di chiusura:
26.63
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $39.00 - MarketBeat
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat
Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Proactive Strategies - Stock Traders Daily
State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World
(AVBP) Pivots Trading Plans and Risk Controls - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases Shares of 10,234 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 6.1% in November - MarketBeat
Charles Schwab Investment Management Inc. Buys 122,641 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
BNP Paribas Financial Markets Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Purchases 169,514 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Suvretta Capital Management, LLC Acquires Additional Shares in A - GuruFocus.com
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Decreases By 11.9% - MarketBeat
Suvretta Capital Management LLC Purchases 132,459 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Trading Report - Stock Traders Daily
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent Biopharma Inc (AVBP) Stock Price & Chart | Trade Now - Capital.com
ArriVent BioPharma (NASDAQ:AVBP) Receives Buy Rating from HC Wainwright - MarketBeat
Medicus Pharma completes IPO, becomes second local life sciences company to go public in 2024 - The Business Journals
ArriVent BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
ArriVent Reports $282.9M Cash Position, Firmonertinib Shows Promise in NSCLC Trial | AVBP Stock News - StockTitan
FMR LLC's Strategic Acquisition of ArriVent BioPharma Inc Shares - GuruFocus.com
(AVBP) On The My Stocks Page - Stock Traders Daily
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MSN
AlphaCentric Advisors LLC Cuts Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
2.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):